AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 281 min read$BOLD

TANG KEVIN sold $54K of BOLD (indirect holdings)

TANG KEVIN sold 18,300 indirectly-held shares of Boundless Bio, Inc. (BOLD) at $2.97 on 2026-08-26. Filed jointly with TANG CAPITAL MANAGEMENT LLC (10% owner).

Original reporting
SEC EDGAR · TANG KEVIN, TANG CAPITAL MANAGEMENT LLC
Published Aug 28, 2026, 8:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BOLD
Neutral
medium confidence
Mentioned
$BOLD
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDNeutralLow
01

Why it matters

A $54k sale by a 10% owner is unlikely to move the stock materially but may be noted by short‑term traders.

02

Market read

Small insider sale with limited trading impact; primarily of interest to ownership‑tracking investors.

03

What to watch

Potential upcoming clinical data or financing events not disclosed in the filing.

Relevance 3/10Novelty 4/10Timing: filing date 2026-08-28

Background

Form 4 filings disclose insider transactions and are primary sources for ownership changes.

Company-level read

Ticker impact

$BOLDNeutralMedium confidence
Context

Insider Kevin Tang sold 18,300 shares of Boundless Bio (BOLD) for $54,351 in a Form 4 filing dated 2026‑08‑26.

Expected impact

Minor short‑term dip or flat price action.

Evidence & confidence

The transaction size ($54k) is small relative to market cap; insider ownership remains sizable, so market reaction is expected to be muted.

Market effects

Sector

None significant; biotech sector unchanged.

Regional

No regional effect.

Global

Minimal.

Counterpoint

What could challenge this read

The sale could signal confidence if the insider plans to re‑acquire later at lower prices.

Key entities

  • Insider
    Kevin Tang

    10% owner of Boundless Bio, Inc.

  • Company
    Boundless Bio, Inc.

    Biotech firm trading under ticker BOLD.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BOLD insider trading history →

Related articles

OCT 27
$LYCAMedAI 8/10

Venrock Healthcare Capital Partners III, L.P. (Koh Bong Y, Shah Nimish P) purchased $37.7M of LYCA (indirect holdings)

Venrock Healthcare Capital Partners III, L.P. purchased 2,045,440 indirectly-held shares of Lycia Therapeutics, Inc. (LYCA) at an average of $18.41 ($18.00–$26.97, $37.65M total) across 6 trades over 2026-10-23 to 2026-10-27. Filed jointly with VHCP Co-Investment Holdings III, LLC (10% owner), VHCP Management III, LLC (10% owner), Venrock Healthcare Capital Partners EG, L.P. (10% owner), VHCP Management EG, LLC (10% owner), Venrock Healthcare Capital Partners XP, L.P. (10% owner), VHCP Management XP, LLC (10% owner), Koh Bong Y (10% owner) and Shah Nimish P (10% owner).

SEC EDGAR1 min